In an attempt to expedite access to next-generation cell therapies, Galapagos has agreed to acquire CellPoint in an all-cash transaction of up to €225 M (US$237.19 M), and AboundBio for US$14 M. The deals provide Galapagos with full access to CellPoint’s automated point-of-care supply model as well as AboundBio’s next-generation fully human antibody-based therapeutics platform. The acquisitions will position Galapagos as an innovator in cell therapy and reinforce its portfolio within the new therapeutic area.